S. Verbois

发表

Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.

H. Rosenfeldt, K. Benson, M. Ricci, 2010, Toxicology and applied pharmacology.

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

R. Pazdur, R. Justice, R. Sridhara, 2010, Clinical Cancer Research.

Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs.

Timothy J Kropp, Thomas Colatsky, T. Colatsky, 2011, Regulatory toxicology and pharmacology : RTP.

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

E. Rock, R. Pazdur, V. Goodman, 2007, Clinical Cancer Research.

Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

R. Pazdur, J. Gobburu, R. Lostritto, 2004, Clinical Cancer Research.

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

E. Rock, R. Pazdur, V. Goodman, 2007, The oncologist.

Traumatic brain injury reduces hippocampal alpha7 nicotinic cholinergic receptor binding.

S. Scheff, P. Sullivan, J. R. Pauly, 2000, Journal of neurotrauma.

Chronic intermittent nicotine administration attenuates traumatic brain injury-induced cognitive dysfunction

S. Scheff, J. R. Pauly, S. Verbois, 2003, Neuroscience.

Time-dependent changes in rat brain cholinergic receptor expression after experimental brain injury.

S. Scheff, J. R. Pauly, S. Verbois, 2002, Journal of neurotrauma.

Chronic nicotine treatment attenuates α7 nicotinic receptor deficits following traumatic brain injury

S. Scheff, J. R. Pauly, S. Verbois, 2003, Neuropharmacology.